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hanne.van.ballegooijen@vu.nlAbstractObjective: A disturbed vitamin D–parathyroid hormone (PTH)–calcium axis may play a role in
the pathogenesisofheart failure. Therefore, we investigated whether lower 25-hydroxyvitamin
D (25(OH)D) and higher PTH are cross sectionally and after 8 years of follow-up associated with
higher B-type natriuretic peptide (BNP) levels in older men and women.
Design and methods: We measured baseline 25(OH)D, PTH, and BNP in 502 subjects in
2000–2001 in the Hoorn Study, a population-based cohort. Follow-up BNP was available in
2007–2009 in 278 subjects. Subjects were categorized according to season- and sex-specific
quartiles of 25(OH)D and PTH at baseline. We studied the association of 25(OH)D and PTH
quartiles with BNP using linear regression analyses adjusting for confounders. Analyses were
stratified by kidney function estimated glomerular filtration rate (eGFR;%60 ml/min per
1.73 m2) because of significant interaction.
Results: At baseline, subjects had a mean age of 69.9G6.6 years, mean 25(OH)D level was
52.2G19.5 nmol/l and mean PTH 6.1G2.4 pmol/l. Cross sectionally, 25(OH)D was associated
with BNP in subjects with impaired kidney function (eGFR%60 ml/min) only. The association
attenuated after adjustment for PTH. PTH was cross sectionally associated with BNP, also in
subjects with impaired kidney function only: regression coefficient of highest quartile
9.9 pmol/l (95% confidence interval 2.5, 17.4) with a significant trend across quartiles. Neither
25(OH)D nor PTH was associated with BNP in longitudinal analyses.
Conclusion: This study showed overall no strong association between 25(OH)D and BNP.
However, PTH was associated with BNP in subjects with impaired kidney function and may
point to a potential role in myocardial function.Key Words
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2–10 1 :49IntroductionWorldwide, vitamin D deficiency is highly prevalent
among older people (1). Vitamin D can be either ingested
orally or can be synthesized by the human skin by
exposure to the solar ultraviolet B spectrum (1). Sub-
stantial decrease in serum 25-hydroxyvitamin D
(25(OH)D) levels, the principal circulating storage form,
will result in proportionally higher parathyroid hormone
(PTH) levels to maintain serum and total body calcium.
Vitamin D and PTH receptors have been detected in
(skeletal and in) cardiac muscle (2, 3), indicating a
potential functional role in myocardial function. Thereby,
a disturbed vitamin D–PTH–calcium axis – which includes
calcitriol the active form of vitamin D that is produced in
the kidney – may play a role in the pathogenesis of heart
failure (HF) (4).
Loss of heart function or HF is a growing problem in
our aging society, therefore determination of factors that
can influence loss of heart function is of paramount
importance. Recent evidence suggests a number of
mechanisms where 25(OH)D and PTH may influence the
pathophysiology of HF. These include actions on blood
pressure via the renin–angiotensin system, calcium
handling, reduction of proinflammatory cytokines, left
ventricular mass, and improvements in endothelial
function (4, 5, 6).
Plasma B-type natriuretic peptide (BNP) is a neuro-
hormone that is primarily secreted in the cardiomyocytes
in response to ventricular stretch and pressure overload, so
the BNP level is determined by many aspects of cardiac
function (7). Subjects with BNP levels below 100 pg/ml
(equivalent to 28 pmol/l) have no symptomatic HF.
However, in asymptomatic subjects, higher BNP levels –
but still below the threshold of 100 pg/ml – indicate a
higher future risk of developing HF, atrial fibrillation,
stroke, transient ischaemic attack, and death (8). This
makes BNP a global marker for myocardial deterioration.
Patients with elevated BNP levels have often normal
cardiac function when measured by conventional echo-
cardiography but suffer from preclinical systolic and
diastolic dysfunction as assessed by tissue Doppler imaging
(9). Circulating levels of NT-proANP – released by
cardiomyocytes in the atria – are largely increased in
patients with HF and are a predictor of disease severity (10).
This suggests that a moderate increase in plasma BNP level
may serve as a sensitive marker for early myocardial
deterioration (8, 9), which cannot be detected with
conventional echocardiography. The relationship betweenhttp://www.endocrineconnections.org
DOI: 10.1530/EC-12-003325(OH)D and PTH in relation to kidney function is well-
known, whereas the relationship with BNP is novel (11).
Observational data in patients with HF suggest that
low 25(OH)D levels and high PTH levels are common and
are both associated with higher BNP levels (12, 13). This
indicates that ventricular stretch due to pressure overload
is the primary driver of the secretion of BNP in the
cardiomyocytes and represents a long-term indirect
measure of cardiac function. So far, there are no
observational data available for 25(OH)D and PTH in
relation to BNP levels in a general population. We
therefore tested the hypothesis whether lower 25(OH)D
levels and higher PTH levels are associated with higher
BNP levels in older men and women, both cross
sectionally and after 8 years of follow-up.Materials and methods
Study sample
The Hoorn Study started in 1989 and included 2483 men
and women aged 50–75 years, from the Netherlands.
Detailed descriptions of the study concept and baseline
measurements have been published previously (14). The
current study was done in 648 subjects who had
examinations in 2000–2001 (considered as baseline) (15).
Subjects with no assessment of PTH (nZ15) or 25(OH)D
(nZ26) were excluded. Subjects with no baseline BNP
measurement were also excluded (nZ105). This resulted
in 502 subjects with vitamin D, PTH, and BNP measure-
ments for cross-sectional analyses.
In 2007–2009, w8 years after baseline, 169 subjects
were not willing to participate for the follow-up exami-
nations. We excluded subjects with no BNP measurement
at follow-up (nZ55). Our study sample consisted of 278
subjects for longitudinal analyses. The study complied
with the Declaration of Helsinki, the local Ethics
Committee approved the study, and all subjects provided
written informed consent.Blood measurements
Vitamin D status was assessed by measuring serum
25(OH)D levels by a competitive binding protein assay
(DiaSorin, Stillwater, MN, USA) (16), a valid marker to
measure vitamin D status (17). The inter-assay coefficient
of variation (CV) was 10–15% (16). Serum intact PTH was 2012 The Authors. Published by BioScientifica Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
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Stillwater, MN, USA). Laboratory measurements were
conducted at the VU University Medical Center,
Amsterdam.
Plasma BNP was determined in spare frozen EDTA
samples that had been stored at K80 8C for 4 years.
At baseline, BNP was determined using an immunoradio-
metric assay (Shionoria, Osaka, Japan). Inter- and intra-
assay variability coefficients were analyzed within the
normal range!10%. At follow-up, BNP was determined in
spare frozen EDTA samples that had been stored atK80 8C
for 2 years using a noncompetitive immunofluorometric
assay (TRIAGE, Biosite, San Diego, CA, USA). Intra-assay
CV was 3.5% and the total CV was 12.3%.Additional measurements at baseline
Fasting glucose, post-load glucose after an oral glucose
tolerance test, high-density lipoprotein (HDL) and low-
density lipoprotein cholesterol, and triglycerides were
measured as described elsewhere (15). Weight (kg) and
height (m) were measured while subjects were wearing
light clothing and no shoes. Body mass index (BMI) was
calculated as weight (kg) divided by height squared (m2).
Waist circumference (cm) was measured at the level
midway between the lowest rib and the iliac crest. Blood
pressure (mmHg) was measured at the right-upper arm
after 5 min at rest in a sitting position, using a random-
zero sphygmomanometer (Hawksley–Gelma Ltd., Lancing,
UK), and the average of two consecutive measurements
was used. Arterial hypertension was defined as systolic
blood pressure (SBP) R140 mmHg, diastolic blood
pressure (DBP)R90 mmHg and/or use of antihypertensive
medication. As an estimate of kidney function, glomerular
filtration rate (eGFR) was calculated using serum creati-
nine values – determined using the Jaffe´ method –
according to the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation (18).
Subjects filled out questionnaires to obtain self-
reported information on medication use, smoking status,
education level, and physical activity. Current smoking
was classified as yes/no. High education level was defined
as higher vocational education or university, medium
level as secondary education, and low level as elementary
school, lower vocational training, or less. Physical activity
(h/day), including commuting activities, leisure time
activities, and occupational activities, was assessed by a
validated questionnaire (16). Time spent on outdoor
physical activity was estimated by adding the time spent
on walking, cycling, and gardening.http://www.endocrineconnections.org
DOI: 10.1530/EC-12-0033Statistical analysis
Baseline characteristics and BNP levels are presented
according to sex- and season-specific 25(OH)D quartiles
and PTH quartiles. Sex- and season-specific quartiles
were used because of the described sex difference in
25(OH)D levels in our study (16) and absolute changes
in 25(OH)D levels (19). We assume that serum 25(OH)D
levels are relatively stable over a long time. A single
25(OH)D measurement can be used in epidemiological
studies in which low 25(OH)D levels are linked to future
diseases (20).
Season classification was based on the date of blood
sampling: winter (December–February), spring (March–
May), summer ( June–August), and autumn (September–
November). We used linear regression analyses to examine
linear trends in the continuous variables across the
quartiles of 25(OH)D and PTH using the categorical
quartile variable as a continuous variable. A c2-test was
performed to test for trend for categorical variables across
the 25(OH)D and PTH quartiles.
We used multiple linear regression analyses to study
the cross-sectional associations between baseline 25(OH)D
quartiles and PTH quartiles in relation to baseline BNP
levels. In the case of 25(OH)D, we considered the highest
25(OH)D quartile as the reference group, in the case of
PTH we considered the lowest quartile as the reference
group. We calculated a P value for trend by adding the
25(OH)D quartiles and PTH quartiles as a continuous
variable to the regression models.
BNP values at baseline and at follow-up were
determined by different methodologies. We added
9.2 ng/ml (equivalent to 2.66 pmol/l) to the baseline
values of BNP as suggested by Hammerer–Lercher et al.
(21). Differences between follow-up and baseline BNP were
calculated to investigate changes within 25(OH)D and
PTH quartiles.
Multiple linear regression analyses were used to study
the association between baseline 25(OH)D quartiles and
PTH quartiles and BNP levels after 8 years of follow-up.
We adjusted for the baseline value by adding the baseline
BNP as an independent variable to the regression models.
We adjusted for potential confounding in the
regression models by adding potential confounders one
by one to the regression models. Potential confounders
considered were: waist circumference, BMI, outdoor
activities, blood pressure, cholesterol, triglycerides, glu-
cose levels, antihypertensive or lipid lowering medication
use and eGFR. Variables that changed the regression 2012 The Authors. Published by BioScientifica Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
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4–10 1 :51coefficients of 25(OH)D or PTH quartiles more than 10%
were included in the models. eGFR was added to describe
separately the influence of adjustment for kidney func-
tion. In the case of PTH, we also adjusted for total
25(OH)D, because vitamin D deficiency is a known risk
factor for hyperparathyroidism.
We tested for effect modification by presence of prior
cardiovascular disease (CVD) because CVD treatment and
self-care could change BNP. We also tested for effect
modification by the presence of type 2 diabetes because
subjects were invited according to their glucose tolerance
status. Furthermore, we tested for interaction by presence
of impaired kidney function (eGFR %60 ml/min per
1.73 m2) because lower kidney function may result in
lower conversion of calcitriol (active form of vitamin D)
and may increase PTH (22). When significant interaction
terms were found (P value interaction term !0.10),
analyses were stratified accordingly.
All reported P values were two-sided and values!0.05
were considered statistically significant. Statistical
analyses were conducted using the statistical program
PASW 17.0 (SPSS, Inc., Chicago, IL, USA).Results
Baseline serum 25(OH)D, PTH, and BNP were available for
502 subjects. Mean 25(OH)D level was 52.2G19.5 nmol/l
and mean PTH was 6.1G2.4 pmol/l. Plasma BNP showed a
distribution skewed to the right, median BNP was
7.7 pmol/l and interquartile range was 4.0, 11.3 pmol/l.
The BNP residuals were normally distributed and therefore
BNP is treated in its natural scale.
Baseline characteristics according to sex- and season-
specific 25(OH)D quartiles showed that subjects with
lower 25(OH)D levels were significantly older, were more
often hypertensive, had less physical activities and
outdoor activities, had higher BMI, larger waist circum-
ference, higher blood pressure (SBP and DBP), higher
post-load glucose levels, higher triglycerides, lower HDL
cholesterol, higher PTH levels, and higher BNP levels with
significant trends across the 25(OH)D quartiles (Table 1).
Subjects in the third 25(OH)D quartile had on average the
lowest BNP levels. Subjects with higher PTH levels were
significantly older, had more often type 2 diabetes, were
more often hypertensive, had higher BMI, larger waist
circumference, higher blood pressure (SBP and DBP),
higher fasting blood glucose, higher post-load glucose,
lower HDL cholesterol, lower 25(OH)D levels, and higher
BNP levels with significant trends across the PTH quartiles
(Table 1).http://www.endocrineconnections.org
DOI: 10.1530/EC-12-0033Cross-sectional analyses
We found effect modification by eGFR for the cross-
sectional association of 25(OH)D with BNP (P!0.001) and
not by prior CVD (PZ0.162) or by the presence of type 2
diabetes (PZ0.100). Therefore, we stratified the analyses
based on kidney function: impaired kidney function
(eGFR %60 ml/min per 1.73 m2) and normal kidney
function (eGFR O60 ml/min per 1.73 m2). Stratification
based on CKD stage is not possible because of too few
subjects in the more severe stages of kidney function.
Results of the linear regression analyses showed that in
subjects with impaired kidney function the lowest
25(OH)D quartile was associated with higher BNP with a
significant trend (PZ0.031) across the 25(OH)D quartiles
(Fig. 1). In other words, (on average) a 62% lower level of
25(OH)D resulted in a 82% higher BNP. Further adjust-
ment for the residual kidney function – included as eGFR
continuously – resulted in more pronounced results (P
trend 0.013). In subjects with normal kidney function
(eGFRO60 ml/min), no association was observed between
25(OH)D and BNP (Fig. 1) and also no association was
found when 25(OH)D was treated as a continuous variable
regression coefficient: 0.1 (K0.1, 0.1).
We also found effect modification by eGFR for the
cross-sectional association between PTH and BNP
(P!0.001) but not by prior CVD (PZ0.151) or by the
presence of type 2 diabetes (PZ0.171). In subjects with
impaired kidney function (eGFR %60 ml/min), the high-
est PTH quartile was associated with higher BNP with a
significant trend across the categories (PZ0.003; Fig. 2). In
other words, a 142% higher PTH level resulted in a 114%
higher BNP. Further adjustment for kidney function
attenuated the results slightly (P trend 0.007). The results
attenuated only marginally and remained statistically
significant when additionally adjusted for 25(OH)D with
a significant trend across the PTH quartiles: regression
coefficients were first quartile K1.5 (K9.2, 6.1), second
quartile 4.0 (K3.7, 11.8), and third quartile 7.8 (0.0, 15.6;
P trend 0.018). Similar results were seen when PTH was
treated as a continuous variable: regression coefficient was
2.1 (1.1, 3.0) and changed slightly after adjusting for
25(OH)D, 1.9 (0.9, 2.9).
In subjects with normal kidney function, the associ-
ation of PTH with BNP was in the same direction as for
impaired kidney function although the association was
less pronounced (Fig. 2). Regression coefficients were: first
quartile 0.8 (K1.4, 3.0), second quartile 2.0 (K0.1, 4.2),
and third quartile 1.3 (K1.1, 3.7; P trend 0.140). 2012 The Authors. Published by BioScientifica Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
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http://www.endocrineconnections.org
DOI: 10.1530/EC-12-0033Longitudinal analyses
Baseline serum 25(OH)D, PTH, and baseline and follow-up
BNP were available for 278 subjects. Mean 25(OH)D level
was 54.7G18.4 nmol/l and mean PTH was 6.0
G2.1 pmol/l. Median baseline BNP was 7.3 (interquartile
range 4.1, 10.5) and median follow-up BNP was 14.5
(interquartile range 3.8, 25.2) pmol/l.
Also in this subsample, subjects in the lowest 25(OH)D
quartile were significantly older, were more hypertensive,
had less outdoor activities, larger waist circumference,
higher blood pressure (SBP and DBP), and higher eGFR
(data not shown). Subjects in the lowest 25(OH)D quartile
had a significantly larger increase in BNP levels (Table 2).
Subjects in the highest PTH quartile had a significantly
higher BMI and larger waist circumference, higher DBP,
and higher BNP. Changes in BNP did not differ signi-
ficantly between PTH quartiles (Table 3).
Results of the longitudinal analyses in which follow-
up BNP was adjusted for baseline BNP showed no
association of 25(OH)D quartiles or PTH quartiles with
BNP (Tables 2 and 3). We found no significant effect
modification by prior CVD, type 2 diabetes, or eGFR for
25(OH)D and PTH in relation to 8 years changes in BNP.Discussion
In our study sample of older subjects, 25(OH)D was cross
sectionally associated with higher BNP, only in subjects
with impaired kidney function (eGFR %60 ml/min). The
association was not independent of PTH, because adjust-
ing for PTH attenuated the association. PTH was associated
with higher BNP levels independent of 25(OH)D in
subjects with impaired kidney function. In the longitudi-
nal analyses, 25(OH)D and PTH were not associated with
BNP levels after 8 years of follow-up.
The association between 25(OH)D and PTH in relation
to cardiac markers such as BNP has not been studied
extensively. In line with our study, cross-sectional studies
showed that 25(OH)D was inversely associated with BNP
levels in patients referred for coronary angiography (12,
23, 24). In randomized trials, a high dosage of vitamin D
supplementation reduced BNP levels in type 2 diabetes
patients (25) and HF patients (26). Cross sectionally, PTH
was positively associated with BNP (13) in HF patients and
not associated with BNP in patients on dialysis (24).
Our study is the first to investigate the association of
25(OH)D and PTH in relation to BNP in a general
population. There were several reasons that could possibly
explain why we were not able to show longitudinal 2012 The Authors. Published by BioScientifica Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Figure 1
Regression coefficients of baseline 25(OH)D quartiles with B-type
natriuretic peptide stratified by estimated glomerular filtration rate
!60 ml/min in 502 older subjects. eGFR, estimated glomerular filtration
rate; Q, quartile; Regression model: adjusted for age, smoking, outdoor
activities, body mass index, triglycerides, HDL cholesterol. P for trend:
impaired eGFR, 0.031; normal eGFR, 0.469.
Figure 2
Regression coefficients of baseline parathyroid hormone quartiles with
B-type natriuretic peptide stratified by estimated glomerular filtration rate
!60 ml/min in 502 older subjects. eGFR, glomerular filtration rate;
Q, quartile; Regression model: adjusted for age, smoking, outdoor
activities, body mass index, triglycerides, HDL cholesterol; P for trend:
impaired eGFR, 0.003; normal eGFR, 0.203.
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7–10 1 :54associations. First, follow-up BNP measurements were
determined using a different methodology than the base-
line measurements. We applied a literature-based correc-
tion factor for baseline BNP, however, this may also
introduce some bias. A second limitation is that missing
data on follow-up BNP may not be missed at random but be
related to conditions such as obesity or underlying cardiac
abnormalities. Included subjects with a baseline and
follow-up measurement were significantly younger (67.4
vs 69.7 years), had less hypertension (62 vs 67%), and lower
waist circumference (93.1 vs 94.1 cm) than subjects who
had no follow-up measurement. Therefore, the associ-
ations of 25(OH)D and PTH with BNP are possibly obscured
because subjects with more cardiac abnormalities were lost
to follow-up. Third, as an estimate of kidney function,
eGFR was calculated with serum creatinine using the Jaffe´
method. Nowadays, the use of standardized creatinine
measures is the standard for estimating GFR (18). This
could have led to an overestimation of the amount of
people with impaired kidney function (eGFR
%60 ml/min). However, it did not influence the ranking
of the subjects according to their kidney function.
Fourth, the subjects for longitudinal analyses had
more homogenous values for 25(OH)D, PTH, and BNPhttp://www.endocrineconnections.org
DOI: 10.1530/EC-12-0033than the subjects for cross-sectional analyses which make
it difficult to show associations; i.e. PTH range (min, max)
decreased from (1.7, 24.3) to (2.5, 14.7) (pmol/l). The
smaller sample size and range of 25(OH)D and PTH could
have contributed to the lack of longitudinal associations.
Another explanation could be that the findings for low
25(OH)D and high PTH observed in HF patients may not
be translatable to a population with nonHF subjects.
Future studies could benefit from a larger sample size and a
wider range of vitamin D and PTH to show potential
longitudinal associations.
In our study, we observed effect modification by
kidney function (eGFR) in the cross-sectional association
of 25(OH)D and BNP. Subjects with low eGFR have lower
kidney-specific 1a-hydroxylase activity (catalyzes
hydroxylation of 25(OH)D to calcitriol, the active form
of vitamin D). Decreased synthesis of calcitriol occurs
already at eGFR values !90 ml/min (27). Stratification
based on the eGFR, led to a stratum in which the subjects
had an eGFR !60 ml/min which suggest decreased
synthesis of calcitriol. Serum calcitriol levels might also
be independently associated with BNP levels. Unfortu-
nately, we did not measure calcitriol levels and are not able 2012 The Authors. Published by BioScientifica Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Table 2 Eight years changes of BNP and associations of baseline 25-hydroxyvitamin D quartiles with BNP after 8 years of follow-up
in 278 subjects.
Serum 25-hydroxyvitamin D (nmol/l)
Mean and range (min–max)
1st Quartile
33.3 (16.7, 62.4)
2nd Quartile
46.8 (33.4, 69.1)
3rd Quartile
59.6 (45.0, 79.2)
4th Quartile
77.9 (63.4, 103.3) P trend
n 65 73 73 67
Absolute BNP changes (pmol/l)a 20.9G33.8 15.0G20.5 13.0G22.7 11.6G14.2 0.023
Regression coefficients
Model 1 2.4 (K6.6, 11.6)b K1.2 (K9.9, 7.6) K1.7 (K10.3, 6.8) Reference 0.593
Model 2 2.6 (K5.3, 10.4) K2.9 (K10.4, 4.6) K1.0 (K8.4, 6.3) Reference 0.654
Model 3 2.4 (K5.6, 10.5) K3.0 (K10.6, 4.6) K1.1 (K8.5, 6.3) Reference 0.691
BNP, B-type natriuretic peptide. Model 1, adjusted for age; model 2, model 1Cadjusted for baseline BNP, smoking, outdoor activities, body mass index,
triglycerides, and high density lipoprotein cholesterol; model 3, model 2CeGFR.
aBaseline BNP adjusted to follow-up BNP by adding 2.66 pmol/l to baseline BNP (17); presented as mean changesGS.D. in pmol/l.
bA positive regression coefficient implies higher BNP.
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8–10 1 :55to draw conclusions whether different calcitriol levels
would be related to BNP.
Higher BNP levels could also be affected by impaired
kidney function given the important inter-relationship
between cardiac and renal dysfunction. There is uncer-
tainty about the effect of declining eGFR and accumu-
lation of BNP concentrations. Nevertheless, recent
evidence suggests that BNP does not accumulate because
of moderate renal impairment but reflects cardiac pro-
duction rather than impaired clearance (28, 29).
Effect modification by kidney function (eGFR) was
also observed for the association between PTH and BNP.
Impaired kidney function results in decreased calcitriol
production and increased PTH levels. If kidneys are not
able to reabsorb calcium, blood calcium levels will fallTable 3 Eight years changes of BNP and associations of baseline pa
in 278 subjects.
Serum pa
Mean and range (min–max)
1st Quartile
3.9 (2.5, 4.8)
2nd Quartile
5.1 (4.1, 6.0)
n 66 72
Absolute BNP changes (pmol/l)a 12.8G15.0 16.4G25.0
Regression coefficients
Model 1 Reference 4.5 (K4.0, 1
Model 2 Reference 1.7 (K5.6, 9
Model 3 Reference 2.0 (K5.4, 9
BNP, B-type natriuretic peptide. Model 1, adjusted for age; model 2, model 1Cb
high density lipoprotein cholesterol; model 3, model 2CeGFR, 25(OH)D.
aBaseline BNP adjusted to follow-up BNP by adding 2.66 pmol/l to baseline BN
bA positive regression coefficient implies higher BNP.
http://www.endocrineconnections.org
DOI: 10.1530/EC-12-0033which stimulates continual secretion of PTH to maintain
blood calcium levels (27). Probably, subjects having high
PTH are more susceptible for the negative influence of
vitamin D on cardiac health.Potential mechanisms
There are potential mechanisms through which low
vitamin D and high PTH could harm the cardiac system.
The underlying pathways are still unclear as the inter-
dependency of vitamin D, PTH, and calcium makes it hard
to study individual factors. Low 25(OH)D is associated
with cardiac cell growth and hypertrophy and can thereby
stimulate BNP secretion (4). Vitamin D could also be
involved in the pathogenesis of arterial hypertension viarathyroid hormone quartiles with BNP after 8 years of follow-up
rathyroid hormone (pmol/l)
3rd Quartile
6.2 (4.7, 7.9)
4th Quartile
8.8 (5.8, 14.7) P trend
73 67
15.8G26.8 15.0G26.3 0.334
3.0)b 2.7 (K5.8, 11.2) 4.2 (K4.4, 12.9) 0.445
.0) 2.0 (K5.1, 9.4) K2.5 (K10.1, 5.2) 0.556
.3) 2.2 (K5.2, 9.6) K2.3 (K10.2, 5.6) 0.603
aseline BNP, smoking, outdoor activities, body mass index, triglycerides, and
P (17); presented as mean changesGS.D. in pmol/l.
 2012 The Authors. Published by BioScientifica Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
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9–10 1 :56stimulation of the renin–angiotensin system (30). Vitamin
D deficiency may predispose to hypertension via elevation
of PTH and disturbed calcium homeostasis, although the
relationship between vitamin D and blood pressure is not
consistent (30). In our study, adjusting for SBP did not
change the associations of PTH and 25(OH)D with BNP
(data not shown). Therefore, our study does not support
the hypothesis that the association between 25(OH)D and
heart function occurs via higher blood pressure. Vitamin D
may also be cardioprotective by its anti-inflammatory
effects as shown in a trial in HF patients (31). Myocardial
calcium homeostasis, which is crucial for the contractility
and electrophysiology of the heart, is also partially
regulated by calcitriol, mediated by its influence on ion
channels and enzymatic reactions (32). Therefore, suf-
ficient vitamin D status could prevent myocardial hyper-
contractility and maintain diastolic function (32).
PTH may influence intracellular signaling by an
increase of intracellular calcium in the cardiomyocytes.
PTH receptors have been demonstrated in the heart,
and in vitro PTH induces hypertrophy of cardiomyocytes
(33, 34). In addition, PTH activates protein kinase C which
could lead to hypertrophic growth and expression of fetal
type proteins in cardiomyocytes (35). This might contrib-
ute to a decline in ejection fraction and increase in BNP
seen in 1 year after parathyroidectomy in patient with mild
primary hyperparathyroidism (34). This hypertrophic
effect of PTH may lead to increased susceptibility for
cardiac diseases and increased risk for HF (35).
Strength of this study is the use of BNP as an easily
obtainable and sensitive marker of early myocardial
deterioration in subjects not suffering from HF. An early
diagnosis of HF could be beneficial to prevent or postpone
HF and cardiac diseases, if modifiable determinants are
known. Our study allowed us to investigate subjects with
moderately increased BNP which already indicates a
higher future risk of developing cardiac diseases (8). The
present findings extend the results of studies that reported
associations between vitamin D and BNP within the
clinical range in select patient groups, such as patients
on dialyses (23, 36) or HF patients (13).
In conclusion, lower 25(OH)D was cross sectionally
associated with higher BNP in subjects with impaired
kidney function only (eGFR%60 ml/min). The association
was not independent of PTH because adjusting for PTH
attenuated the association. Higher PTH was cross section-
ally associated with higher BNP levels in subjects with
impaired kidney function, independent of 25(OH)D.
These findings may point to a potential role for PTH in
myocardial function, although the results should behttp://www.endocrineconnections.org
DOI: 10.1530/EC-12-0033interpreted with caution because of the design, sample
size, and missing values. Confirmation by larger prospec-
tive studies is needed. No longitudinal associations of
25(OH)D and PTH were observed with BNP, which may
have been due to small sample size and/or healthy
selection, or the study population.
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